Inbakicept , CAS No.2135939-52-3

CAS: 2135939-52-3 Cat. No.: I650319
Disponible para pedir
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
★
Size
Alemania (EU)
USA*
Price
Qty
1mg
I650319-1mg
Fabricado bajo pedido · 8–12 semanas
1.302,39€
Enter a quantity for the sizes you want to add.
🧪
Why this grade

for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Descripción general

Inbakicept (ALT-803) is an IL-15 superagonist complex, consisting of IL-15 mutant and IL-15Rα-Fc fusion. Inbakicept magnifies anti-CD20 mAb-mediated NK-cell responses and antibody-dependent cellular cytotoxicity (ADCC). Inbakicept also increases degranulation, IFNγ production in cells

In Vitro

Inbakicept (0.01-1 nM; 20 hr) enhances human NK cell cytotoxicity and increases cytotoxic effector molecule expression. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity AssayCell Line: Daudi, Raji, CD19 + FL cells Concentration: 0.01 nM, 0.1 nM, and 1 nM Incubation Time: 20 hours Result: Increased the human NK cell cytotoxicity on Daudi, Raji, CD19 + FL cells.

In Vivo

Inbakicept (0.2 mg/kg; i.v.; twice weekly, for 2 weeks) enhances rituximab-directed protection from a lethal Daudi lymphoma challenge in mouse model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SCID mice with Daudi models Dosage: 0.02 mg/kg, 0.05 mg/kg, 0.1 mg/kg, and 0.2 mg/kg Administration: Intravenous injection; twice weekly, for 2 weeks Result: Enhanced rituximab-directed control of Raji lymphoma challenge.

IC50& Target:IL-15Rα

Specifications

Mecanismos bioquímicos y fisiológicos
Inbakicept, a dimeric human IL-15 receptor a (IL-15 Ra) sushi domain/human lgG1 Fc fusion protein, is an IL-15 superagonist complex. Inbakicept magnifies anti-CD20 mAb-mediated NK-cell responses and antibody-dependent cellular cytotoxicity (ADCC). Inbakic
Condiciones de almacenamiento de almacenamiento
Store at -20°C
Enviado en
Ice chest + Ice pads
Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.
Tipo de acción
ACTIVATOR

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Certificados (CoA, COO, BSE/TSE y tabla de análisis)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Calculadoras de soluciones
Reseñas

Reseñas de cliente

Preguntas frecuentes

How should this product be stored?
Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.
How is this product shipped?
This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is 2135939-52-3.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.